Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes

Pharmacogenomics

Volumn 15, Issue 2, 2014, Pages 235-249

  Jamaluddin, Jazlina Liza ^a   Huri, Hasniza Zaman ^a,b   Vethakkan, Shireene Ratna ^a   Mustafa, Norlaila ^c  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^c UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

ABCC8; dipeptidyl peptidase 4 inhibitors; KCNJ11; KCNQ1; MTNR1B; PAX4; TCF7L2; WFS1

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DUTOGLIPTIN; INCRETIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; KRP 104; LC 15 0444; LINAGLIPTIN; MELOGLIPTIN; POTASSIUM CHANNEL KCNQ1; SAXAGLIPTIN; SITAGLIPTIN; TENELIGLIPTIN; TRANSCRIPTION FACTOR 7 LIKE 2; TRANSCRIPTION FACTOR PAX4; TRELAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR;

ABCC8 GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC VARIABILITY; GLUCOSE METABOLISM; HUMAN; KCNJ11 GENE; KCNQ1 GENE; MTNR1B GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PAX4 GENE; PHARMACOGENOMICS; PREDICTION; REVIEW; SIGNAL TRANSDUCTION; TCF7L2 GENE; TREATMENT RESPONSE; WFS1 GENE; ADULT; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GENETICS; HOMEOSTASIS; METABOLISM; PATHOLOGY;

ADULT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENZYME INHIBITORS; HOMEOSTASIS; HUMANS; INSULIN-SECRETING CELLS; SIGNAL TRANSDUCTION;

EID: 84893089616     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.234     Document Type: Review

References (77)

1. Liu Y, Zhou DZ, Zhang D et al. Variants in KCNQ1 are associated with susceptibility to Type 2 diabetes in the population of mainland China. Diabetologia 52, 1315-1321 (2006).
2. Brun T, Franklin I, St-Onge L et al. The diabetes-linked transcription factor PAX4 promotes b-cell proliferation and survival in rat and human islets. J. Cell Biol. 167, 1123-1135 (2004).
3. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in Type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6), 1364-1379 (2012).
4. Gautier JF, Fetita S, Sobngwi E, Martin CS. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with Type 2 diabetes. Diabetes Metab. 31(3 Pt 1), 233-242 (2005).
5. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 63(2), 492-498 (1986).
6. Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J. Physiol. 587(1), 27-32 (2009).
7. Mussig K, Staiger H, Machicao F, Haring HU, Fritsche A. Genetic variants affecting incretin sensitivity and incretin secretion. Diabetologia 53, 2289-2297 (2010).
8. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet 368, 1696-1705 (2006).
9. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA. Glucagon-like peptide 1 as a regulator of food intake and body weight: Therapeutic perspectives. Eur. J. Pharmacol. 440, 269-279 (2002).
10. Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in Type 2 diabetes. Diabetes Metab. 34, S65-S72 (2008).
11. Lamont BJ, Li Y, Kwan E, Brown TJ, Gaisano H, Drucker DJ. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J. Clin. Invest. 122(1), 388-402 (2012).
12. Sathananthan A, Man CD, Micheletto F et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in non-diabetic subjects. Diabetes Care 33, 2074-2076 (2010).
13. Stolerman ES, Florez JC. Genomics of Type 2 diabetes mellitus: Implications for the clinician. Nat. Rev. Endocrinol. 5, 429-436 (2009).
14. Foukas LC, Okkenhaug K. Gene-targeting reveals physiological roles and complex regulation of the phosphoinositide 3-kinases. Arch. Biochem. Biophys. 414, 13-18 (2003).
15. Lyssenko V, Eliasson L, Kotova O et al. Pleiotropic effects of GIP on islet function involve osteopontin. Diabetes 60, 2424-2433 (2011).
16. Charbonnel B, Cariou B. Pharmacological management of Type 2 diabetes: The potential of incretin-based therapies. Diabetes Obes. Metab. 13(2), 99-117 (2011).
17. Addison D, Aguilar D. Diabetes and cardiovascular disease: The potential benefit of incretin-based therapies. Curr. Atheroscler. Rep. 13, 115-122 (2011).
18. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157 (2009).
19. Lacy CF. Drug Information Handbook (18th Edition). Armstrong LL, Goldman MP, Lance LL (Eds). Lexi-Comp Inc., OH, USA, 1375-1376 (2009).
20. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am. J. Physiol. Heart Circ. Physiol. 298, H1454-H1465 (2010).
21. Nauck MA. Incretin-based therapies for Type 2 diabetes mellitus: Properties, functions, and clinical implications. Am. J. Med. 124, S3-S18 (2011).
22. Kwon O, Choe EY, Choi Y et al. Discovery of dipeptidyl peptidase-4 gene variants and the associations with efficacy of vildagliptin in patients with Type 2 diabetes-a pilot study. J. Diabetes Metab. 2013, S13-006 (2013).
23. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 32, 193-203 (2009).
24. Duez H, Cariou B, Staels B. DPP-4 inhibitors in the treatment of Type 2 diabetes. Biochem. Pharmacol. 83, 823-832 (2012).
25. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 36, S11-S66 (2013).
26. Kaneko K, Ueki K, Takahashi N et al. Class IA phosphatidylinositol 3-kinase in pancreatic b cells controls insulin secretion by multiple mechanisms. Cell Metab. 12, 619-632 (2010).
27. Fonseca SG, Fukuma M, Lipson KL et al. WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic b-cells. J. Biol. Chem. 280, 39609-39615 (2005).
28. Ishihara H, Takeda S, Tamura A et al. Disruption of the WFS1 gene in mice causes progressive b-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum. Mol. Genet. 13, 1159-1170 (2004).
29. Masana MI, Dubocovich ML. Melatonin receptor signaling: Finding the path through the dark. Sci. STKE 2001(107), pe39 (2001).
30. Miki T, Seino S. Roles of KATP channels as metabolic sensors in acute metabolic changes. J. Mol. Cell. Cardiol. 38, 917-925 (2005).
31. Gloyn AL, Weedon MN, Owen KR et al. Large-scale association studies of variants in genes encoding the pancreatic b-cell KATP channel subunit Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with Type 2 diabetes. Diabetes 52, 568-572 (2003).
32. Wang J, Elghazi L, Parker SE et al. The concerted activities of Pax4 and Nkx2.2 are essential to initiate pancreatic b-cell differentiation. Dev. Biol. 266(1), 178-189 (2004).
33. Damcott CM, Pollin TI, Reinhart LJ et al. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with Type 2 diabetes in the Amish: Replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 55, 2654-2659 (2006).
34. Nelson WJ, Nusse R. Convergence of Wnt, b-catenin, and cadherin pathways. Science 303, 1483-1487 (2004).
35. Chandak GR, Janipalli CS, Bhaskar S et al. Common variants in the TCF7L2 gene are strongly associated with Type 2 diabetes mellitus in the Indian population. Diabetologia 50, 63-67 (2007).
36. Horikoshi M, Hara K, Ito C, Nagai R, Froguel P, Kadowaki T. A genetic variation of the transcription factor 7-like 2 gene is associated with risk of Type 2 diabetes in the Japanese population. Diabetologia 50, 747-751 (2007).
37. Lehman DM, Hunt KJ, Leach RJ et al. Haplotypes of transcription factor 7-like 2 (TCF7L2) gene and its upstream region are associated with Type 2 diabetes and age of onset in Mexican Americans. Diabetes 56, 389-393 (2007).
38. Villareal DT, Robertson H, Bell GI et al. TCF7L2 variant rs7903146 affects the risk of Type 2 diabetes by modulating incretin action. Diabetes 59, 479-485 (2010).
39. Reya T, Clever H. Wnt signalling in stem cells and cancer. Nature 434, 843-850 (2005).
40. Taniguchi CM, Kondo T, Sajan M et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCl/z. Cell Metab. 3, 343-353 (2006).
41. Zhang X, Gan L, Pan H et al. Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. J. Biol. Chem. 277(47), 45276-45284 (2002).
42. Mussig K, Staiger H, Machicao F et al. Association of Type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion. Diabetes 57, 1715-1720 (2009).
43. Shimajiri Y, Sanke T, Furuta H et al. A missense mutation of Pax4 gene (R121W) is associated with Type 2 diabetes in Japanese. Diabetes 50, 2864-2869 (2001).
44. Mellado-Gil JM, Cobo-Vuilleumier N, Gauthier BR. Islet b-cell mass preservation and regeneration in diabetes mellitus: Four factors with potential therapeutic interest. J. Transplant. 10, 1155-1164 (2012).
45. Dohrmann C, Gruss P, Lemaire L. Pax genes and the differentiation of hormone-producing endocrine cells in the pancreas. Mech. Dev. 92, 47-54 (2000).
46. Sosa-Pineda B, Chowdhury K, Torres M, Oliver G, Gruss P. The Pax4 gene is essential for differentiation of insulin-producing b cells in the mammalian pancreas. Nature 386(6623), 399-402 (1997).
47. Greenwood AL, Li S, Jones K, Melton DA. Notch signalling reveals developmental plasticity of Pax4+ pancreatic endocrine progenitors and shunts them to a duct fate. Mech. Dev. 124(2), 97-107 (2007).
48. Larsson LI, St Onge L, Hougaard DM, Sosa Pineda B, Gruss P. Pax4 and 6 regulate gastrointestinal endocrine cell development. Mech. Dev. 79, 153-159 (1998).
49. Salehi M, Aulinger BA, D'Alessio DA. Targeting b-cell mass in Type 2 diabetes: Promise and limitations of new drugs based on incretins. Endocr. Rev. 20(3), 367-379 (2008).
50. Brun T, Hu He KH, Lupi R et al. The diabetes-linked transcription factor Pax4 is expressed in human pancreatic islets and is activated by mitogens and GLP-1. Hum. Mol. Genet. 17(4), 478-489 (2008).
51. Vasavada RC, Gonzalez-Pertusa JA, Fujinaka Y, Fiaschi-Taesch N, Cozar-Castellano I, Garcia-Ocana A. Growth factors and beta cell replication. Int. J. Biochem. Cell Biol. 38, 931-950 (2006).
52. Johnson JD, Bernal-Mizrachi E, Alejandro et al. Insulin protects islets from apoptosis via PDX1 and specific changes in the human islet proteome. Proc. Natl Acad. Sci. USA 103, 19575-19580 (2006).
53. Tan JT, Nurbaya S, Gardner D, Ye S, Tai ES, Ng DP. Genetic variation in KCNQ1 associates with fasting glucose and b-cell function: A study of 3,734 subjects comprising three ethnicities living in Singapore. Diabetes 58, 1445-1449 (2009).
54. Yasuda K, Miyake K, Horikawa Y et al. Variants in KCNQ1 are associated with susceptibility to Type 2 diabetes mellitus. Nat. Genet. 40, 1092-1097 (2008).
55. Unoki H, Takahashi A, Kawaguchi T et al. SNPs in KCNQ1 are associated with susceptibility to Type 2 diabetes in east Asian and European populations. Nat. Genet. 40, 1098-1102 (2008).
56. Bleich M, Warth R. The very small-conductance K+ channel KvLQT1 and epithelial function. Eur. J. Physiol. 440, 202-206 (2000).
57. Vallon V, Grahammer F, Volkl H et al. KCNQ1-dependent transport in renal and gastrointestinal epithelia. Proc. Natl Acad. Sci. USA 102(49), 17864-17869 (2005).
58. Schafer SA, Mussig K, Staiger H et al. A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion. Diabetologia 52, 1075-1082 (2009).
59. Heni M, Ketterer C, Thamer C et al. Glycemia determines the effect of Type 2 diabetes risk genes on insulin secretion. Diabetes 59, 3247-3252 (2010).
60. Fawcett KA, Wheeler E, Morris AP et al. Detailed investigation of the role of common and low-frequency WFS1 variants in Type 2 diabetes risk. Diabetes 59, 741-746 (2010).
61. Florez JC, Jablonski KA, Bayley N et al. TCF7L2 polymorphisms and progression to diabetes in the diabetes prevention program. N. Engl. J. Med. 355, 241-250 (2006).
62. Lyssenko V. The transcription factor 7-like 2 gene and increased risk of Type 2 diabetes: An update. Curr. Opin. Clin. Nutr. Metab. Care 11, 385-392 (2008).
63. Kim H, Choe SA, Ku SY, Kim SH, Kim JG. Association between Wnt signalling pathway gene polymorphism and bone response to hormone therapy in postmenopausal Korean women. Menopause 18(7), 808-813 (2011).
64. Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K. Decreased TCF7L2 protein levels in Type 2 diabetes mellitus correlate with downregulation of GIP-and GLP-1 receptors and impaired beta-cell function. Hum. Mol. Genet. 18(13), 2388-2399 (2009).
65. Bloomgarden ZT. Incretin concepts. Diabetes Care 33(2), e20-e25 (2010).
66. Schafer SA, Tschritter O, Machicao F et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50, 2443-2450 (2007).
67. Nestorowicz A, Glaser B, Wilson BA et al. Genetic heterogeneity in familial hyperinsulinism. Hum. Mol. Genet. 7, 1119-1128 (1998).
68. Cartier EA, Conti LR, Vandenberg CA, Shyng SL. Defective trafficking and function of KATP channels caused by a sulfonylurea receptor 1 mutation associated with persistent hyperinsulinemic hypoglycemia of infancy. Proc. Natl Acad. Sci. USA 98, 2882-2887 (2001).
69. Koster JC, Permutt MA, Nichols CG. Perspectives in diabetes. Diabetes and insulin secretion. The ATP-sensitive K+ channel (KATP) connection. Diabetes 54, 3065-3072 (2005).
70. Gerdin MJ, Mseeh F, Dubocovich ML. Mutagenesis studies of the human MT2 melatonin receptor. Biochem. Pharmacol. 66, 315-320 (2003).
71. Dubocovich ML. Melatonin receptors: Role on sleep and circadian rhythm regulation. Sleep Med. 8, S34-S42 (2007).
72. Lyssenko V, Nagorny CL, Erdos MR et al. Common variant in MTNR1B associated with increased risk of Type 2 diabetes and impaired early insulin secretion. Nat. Genet. 41(1), 82-88 (2009).
73. Liu C, Wu Y, Li H et al. MTNR1B rs10830963 is associated with fasting plasma glucose, HbA1c and impaired beta-cell function in Chinese Hans from Shanghai. BMC Med. Genet. 11, 59 (2010).
74. Sparsø T, Bonnefond A, Anderson E et al. G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and Type 2 diabetes through an impaired glucose-stimulated insulin release. Diabetes 58, 1450-1456 (2009).
75. Simonis-Bik AM, Nijpels G, van Haeften TW et al. Gene variants in the novel Type 2 diabetes loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic b-cell function. Diabetes 59, 293-301 (2010).
76. Shimajiri Y, Shimabukuro M, Tomoyose T et al. Pax4 mutation (R121W) as a prodiabetic variant in Okinawans. Biochem. Biophys. Res. Commun. 302(2), 342-344 (2003).
77. Chambers JC, Zhang W, Zabaneh D et al. Common genetic variation near melatonin receptor MTNR1B contributes to raised plasma glucose and increased risk of Type 2 diabetes aming Indian Asians and European Caucasians. Diabetes 58, 2703-2708 (2009).